Terek Peterson, Senior Director of Global Statistical Standards, Chiltern
Dave Izard, Senior Director of Clinical Data Standards, Chiltern
In this episode, we hear from two experts on the FDA’s regulations regarding electronic submissions. They cover issues such as what has changed over the last 3 years, the latest FDA guidance documents, reasons for complying, and deploying standards when clinical development … Read More »
Heather Gartman, Managing Director, Public Relations Group, inVentiv Health
Heather Gartman discusses patient advocacy in the mental health space, including problem with underfunded research, the numerous stakeholders involved, and ways pharma and these stakeholders can come together to better support this extremely important area of the healthcare … Read More »
Peter Belden, President of ICS, an AmerisourceBergen company
In this episode, Pete Belden talks about the role of third-party logistics in the commercialization process, how manufactures should solve challenges using 3PL partners, and where 3PL services are headed in the future.
Dr. Kate Perry, Director of Behavioral Science, Atlantis Healthcare
Dr. Perry discusses the complexities of self-management across chronic disease. We explore the application of health psychology and the role of technology in helping pharma support patients to stay on track with their prescribed treatment.
Prithul Bom, MBA, RAC, ASQ-CSQE, Senior Director, Scientific Affairs, TA Leader for Medical Device & Diagnostics, Chiltern
Lisa Moore, PhD, RN, Senior Director, Scientific Affairs, TA Leader for Cardiovascular, Chiltern
In this episode, we talk about how smartphones intersect with medical devices, what makes an app a mobile medical app, why companies should include a mobile medical app with their Class II or Class III medical devices, why Human Factors and Usability Engineering are so impor … Read More »
Chiquita Brooks-LaSure, Managing Director, Manatt Health
Joel S. Ario, Managing Director, Manatt Health
The 2016 election will have a major impact on both federal and state healthcare policy. To be sure your organization is prepared for all the possibilities, it’s critical to understand the political dynamics that will be at play under each potential scenario—and what they wil … Read More »
Angie Wheeler, CEO, Cello Health Insight, Chicago
Jim McDermott, Vice President, Cello Health BioConsulting
John Howley, Managing Director, Cello Health Communications, US
In this episode, our panel of experts will talk about the state of the rare disease space, and how to succeed in this growing arena. There is also a related white paper on this topic, which you can download using the link at the bottom of this listing.
Chuck Reed, Group Vice President, Pharmacy Innovation & Solutions, AmerisourceBergen Drug Corporation
In this episode, Chuck Reed talks about the Elevate Provider Network, how it helps provide better patient care, and how it benefits other stakeholders in the prescription medicine ecosystem.
Michael Carlin, Vice President, TrialCard
In this episode, Michael Carlin of TrialCard discusses rare diseases and orphan drugs, and how life sciences companies can overcome the many business challenges associated with these types of disease states. There is also a related white paper entitled “No Patient Left Behin … Read More »
Troy Johnson, Senior Consultant Analytics, TrialCard Market Access Solutions
This podcast episode discusses some of the environmental factors reinforcing the importance of co-pay program optimization and goes into detail on the various aspects of the program that can be optimized and common results. A real-world example of a program optimization ana … Read More »
Johanna Skilling, EVP, Director of Planning, US, Ogilvy CommonHealth Worldwide
The World Economic Forum has named collaboration as the key to global growth: public-private partnerships between companies large and small, NGOs, government agencies and academia are the single largest corporate trend of the decade. And why? The world’s problems are increas … Read More »